

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

JAK2 antibody [EPR108(2)]

RRID:AB_10865183

Type: Antibody

Proper Citation

Abcam Cat# ab108596, RRID:AB_10865183

Antibody Information

URL: http://antibodyregistry.org/AB_10865183

Proper Citation: Abcam Cat# ab108596, RRID:AB_10865183

Target Antigen: JAK2 antibody [EPR108(2)]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Western Blot; Immunocytochemistry; ICC, WB

Antibody Name: JAK2 antibody [EPR108(2)]

Description: This monoclonal targets JAK2 antibody [EPR108(2)]

Target Organism: rat, mouse, human

Antibody ID: AB_10865183

Vendor: Abcam

Catalog Number: ab108596

Record Creation Time: 20250819T205215+0000

Record Last Update: 20250819T210532+0000

Ratings and Alerts

No rating or validation information has been found for JAK2 antibody [EPR108(2)].

No alerts have been found for JAK2 antibody [EPR108(2)].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mao J, et al. (2024) Balancing macrophage polarization via stem cell-derived apoptotic bodies for diabetic wound healing. *Med (New York, N.Y.)*, 5(2), 148.

Fu GQ, et al. (2024) Exosomes derived from vMIP-II-Lamp2b gene-modified M2 cells provide neuroprotection by targeting the injured spinal cord, inhibiting chemokine signals and modulating microglia/macrophage polarization in mice. *Experimental neurology*, 377, 114784.

Zhao Z, et al. (2024) *Helicobacter pylori* activates SLFN4+MDSCs to accelerate gastric intestinal metaplasia. *iScience*, 27(11), 111255.

Deng C, et al. (2024) Extracellular-vesicle-packaged S100A11 from osteosarcoma cells mediates lung premetastatic niche formation by recruiting gMDSCs. *Cell reports*, 43(2), 113751.

Yu Y, et al. (2023) Mechanism of piR-1245/PIWI-like protein-2 regulating Janus kinase-2/signal transducer and activator of transcription-3/vascular endothelial growth factor signaling pathway in retinal neovascularization. *Neural regeneration research*, 18(5), 1132.

Chang W, et al. (2022) OTUB2 exerts tumor-suppressive roles via STAT1-mediated CALML3 activation and increased phosphatidylserine synthesis. *Cell reports*, 41(4), 111561.

Bian G, et al. (2021) DGT, a novel heterocyclic diterpenoid, effectively suppresses psoriasis via inhibition of STAT3 phosphorylation. *British journal of pharmacology*, 178(3), 636.

Liu S, et al. (2021) Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. *Cell reports. Medicine*, 2(10), 100411.

Schulz-Heddergott R, et al. (2018) Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. *Cancer cell*, 34(2), 298.

Cui S, et al. (2017) CXCL8 Antagonist Improves Diabetic Nephropathy in Male Mice With Diabetes and Attenuates High Glucose-Induced Mesangial Injury. *Endocrinology*, 158(6), 1671.